In this study, we seek to assess the performance of these models for the identification of CTRCD during cancer treatment by determining the discrimination and calibration of these three models in a cohort of women with HER2+ breast cancer who received treatment with chemotherapy and trastuzumab in routine clinical practice. This evidence concerns the gene ERBB2 and cancer.